Object. Low-grade, or Spetzler-Martin (SM) Grades I and II, arteriovenous malformations (AVMs) are associated with lower surgical morbidity rates than higher-grade lesions. While radiosurgery is now widely accepted as an effective treatment approach for AVMs, the risks and benefits of the procedure for low-grade AVMs, as compared with microsurgery, remain poorly understood. The authors of this study present the outcomes for a large cohort of low-grade AVMs treated with radiosurgery.
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A rteriovenous malformations (AVMs) are among the most complex intracranial vascular pathologies and are associated with wide variations in clinical presentation, location, size, and angioarchitecture. 5 There is a paucity of prospective, multicenter data regarding the natural history of and long-term treatment outcomes for AVMs, owing to their rarity. Therefore, AVMs continue to represent a significant challenge to the cerebrovascular community, and opinions differ regarding the optimal management of these lesions. 6, 9, 41, 42 A number of AVM grading systems have been developed over the years with the ultimate goal of predicting treatment outcomes based on AVM subgroup. 19, 30, 40, 43, 49 For surgical planning, however, no classification is more widely used than the Spetzler-Martin (SM) grading scale because of its simplicity and reliability in predicting microsurgical AVM outcomes. 40 Based on the composition of the Spetzler-Martin grading scale, Grade I and II, or low-grade, AVMs are typically small, drain into the superficial venous system, and are located in noneloquent cortex. Despite having decreased rates of microsurgical morbidity compared with their highergrade counterparts, low-grade AVMs have not been definitively shown to have more benign natural histories. 12, 23 In fact, small AVMs may be more prone to hemorrhage than larger ones as a result of higher pressures in the feeding arteries. 39 While microsurgery is the traditional approach for AVM obliteration, in the last 2 decades radiosurgery has emerged as an acceptable treatment alternative. 10, 32, 45 However, the risk-to-benefit profile of radiosurgery for lowgrade AVMs has yet to be fully delineated. 14, 23 We hypothesize that radiosurgery offers an effective, low-risk treatment option for patients harboring Spetzler-Martin Grade I or II AVM. To test this hypothesis, we critically analyzed our low-grade AVM radiosurgery experience.
Methods

Patient Population
Over the period from 1989 to 2012, approximately 1450 AVM cases were treated with Gamma Knife radiosurgery at the University of Virginia and registered in a prospective, institutional review board-approved database. We performed a retrospective review of this prospectively collected database. We identified all patients with SM Grade I or II AVM who had at least 2 years of radiological follow-up. All patients with less than 2 years of follow-up were excluded except those with AVMs that were obliterated prior to the 2-year follow-up.
Radiological Evaluation and Radiosurgical Targeting
An attending neurosurgeon and neuroradiologist at the University of Virginia evaluated each patient's neuroimaging studies, including digital subtraction angiography (DSA), CT, and MRI. Each AVM's size, location, morphology, angioarchitecture, and SM grade were assigned at the time of radiosurgical treatment. Our Gamma Knife radiosurgery technique has been described elsewhere. 45 Prior to 1991, DSA and CT were routinely used for radiosurgical planning. After 1991, MRI was routinely used to enhance the precision of nidus definition. Dose planning was performed with the Kula software from 1989 to June 1994, after which it was replaced by the Gamma Plan software. Repeat radiosurgery was considered for patients who demonstrated a patent nidus 3 years after a prior radiosurgery.
Radiological and Clinical Follow-Up
For the first 2 years following radiosurgery, standard radiological follow-up consisted of MRI every 6 months. Subsequent to 2 years' follow-up, annual MRI was performed. Additional imaging, either CT or MRI, was performed for neurological deterioration. An attending neurosurgeon and neuroradiologist at our institution evaluated all postradiosurgery neuroimaging. Hemorrhage was defined by imaging only, regardless of clinical status. Obliteration was defined on MRI as the absence of flow voids or on DSA as the absence of abnormal arteriovenous shunting. Digital subtraction angiography was performed only to confirm the complete AVM obliteration demonstrated on MRI. Perinidal T2-weighted hyperintensities identified on postradiosurgery MRI were defined as radiation-induced changes (RICs). These changes were deemed symptomatic when correlated with clinical manifestation, typically headache, seizure, and/or focal neurological deficit. Since the University of Virginia is a tertiary care referral center for radiosurgery, clinical follow-up consisted of a combination of direct follow-up via return appointments or admissions to the University of Virginia clinics or hospital, respectively, and indirect follow-up via correspondence with outside hospitals and local primary care physicians.
Statistical Analysis
All statistical analyses were performed with the IBM SPSS 20 statistical software program. The actuarial obliteration rates following radiosurgical treatment were calculated with Kaplan-Meier analysis. Cox proportional-hazards regression analysis was used to identify predictors of obliteration, and logistic regression analysis was used to identify predictors of postradiosurgery hemorrhage and RICs. Factors analyzed in these analyses included sex, age, preradiosurgery hemorrhage, preradiosurgery embolization, AVM volume, AVM location (superficial vs deep and noneloquent vs eloquent), location of draining veins (superficial vs deep), number of draining veins (single vs multiple), prescription dose, number of isocenters, radiological presence of RIC, SM grade, radiosurgery-based AVM scale (RBAS) score, and Virginia Radiosurgery AVM Scale (Virginia RAS) score.
The patient, AVM, and treatment characteristics listed above were initially subjected to univariate analysis, either Cox proportional-hazards or logistic regression analysis. The covariates were subjected to multivariate analysis if the p value in the aforementioned univariate analysis was statistically significant (that is, < 0.05) using a Cox proportional-hazards regression model for covariates associated with obliteration and a logistic regression model for covariates associated with postradiosurgery hemorrhage or RIC with a backward likelihood ratio condition. The validity of the proportional-hazards assumption was detected using a log-minus-log survival plot. A hazard or odds ratio, 95% confidence interval, and p value were determined for each analyzed factor. Statistical significance was defined as a hazard or odds ratio with a 95% confidence interval not including 1.0 and a p value < 0.05. All statistical studies were 2-sided. The total number of risk years was calculated by the sum of the time intervals between radiosurgery and obliteration or the last radiological follow-up in nonobliterated AVMs. The annual postradiosurgery hemorrhage risk was defined by dividing the total number of individual postradiosurgery hemorrhages by the total number of risk years. Additionally, we identified 3 pairs of selected low-grade AVM subgroups and compared the outcomes between each pair: 1) nonembolized versus embolized lesions, 2) lesions with superficial versus deep venous drainage, and 3) lesions located in noneloquent versus eloquent cortex. The actuarial obliteration rates were compared with the log-rank test, the rates of cumulative RIC were compared with the chi-square test with Yates' correction, and the rates of symptomatic and permanent RICs were compared with Fisher's exact test.
Results
Patient Population
Five hundred two patients harboring SM Grade I or II AVM were eligible for analysis and consisted of 253 males (50.4%) and 249 females (49.6%) with a median age of 35.2 years. Seventy-nine patients (15.7%) were under the age of 18 years. Preradiosurgery therapies included microsurgical removal in 55 patients (11.0%) and embolization in 101 patients (20.1%). The most common presenting symptoms were hemorrhage in 235 patients (46.8%), seizure in 126 patients (25.1%), and headache in 83 patients (16.5%). The characteristics of the patient population are summarized in Table 1 .
Radiosurgery Treatment Parameters and AVM Characteristics
The median radiosurgical parameters for the initial radiosurgery procedures were as follows: nidus volume 2. 40 The RBAS score-a weighted sum of patient age, AVM volume, and AVM location-was a mean of 1.04, median of 1.03, and range of 0.21-2.95. 49 The Virginia RAS score, which is based on history of preradiosurgery hemorrhage, AVM volume, and eloquence of AVM location, was 0-1 in 210 patients (41.8%), 2 points in 202 patients (40.2%), 3 in 77 patients (15.3%), and 4 in 13 patients (2.6%). 43 Table 2 details the AVM characteristics and radiosurgical parameters.
Radiological Outcomes Following Radiosurgery
The overall radiological follow-up was a mean of 67.5 months (5.6 years), median of 47.9 months (4.0 years), and range of 5.7-239.4 months (0.5-20.0 years). Complete obliteration of the AVM nidus was confirmed by DSA in 304 patients (60.6%) and demonstrated by MRI alone in 78 patients (15.5%) for a cumulative AVM obliteration rate of 76.1%. Excluding all patients with less than 2 years of follow-up regardless of AVM obliteration yielded an obliteration rate of 71.0% (294 of 414 patients), consisting of 15.0% (62 of 414 patients) by MRI alone and 56% (232 of 414 patients) by DSA. The time to obliteration was a median of 39.5 months (3.3 years) with a range of 5.7-192.8 months (0.5-16.1 years). The actuarial obliteration rates at 3, 5, 7, and 10 years were 41%, 66%, 75%, and 80%, respectively. The obliteration rate of low-grade AVMs over time is shown in Fig. 1 .
Obliteration rates were not significantly different between unruptured and ruptured AVMs (p = 0.132), nor between SM Grade I and II AVMs (p = 0.351). The actuarial obliteration rates of low-grade AVMs treated with embolization before radiosurgery were 24%, 34%, 49%, and 55% at 3, 5, 7, and 10 years, respectively. For low-grade AVMs without prior embolization, the actuarial obliteration rates were 45%, 74%, 81%, and 87%, respectively. Arteriovenous malformations without preradiosurgery embolization had significantly higher obliteration rates than embolized AVMs (p < 0.001). Figure 2 shows the obliteration rate over time for nonembolized and embolized low-grade AVMs. When classified by the Virginia RAS, AVMs with a score of 0-1 had actuarial obliteration rates of 54%, 78%, 85%, and 92% at 3, 5, 7, and 10 years, respectively; those with a score of 2-4 had actuarial obliteration rates of 32%, 58%, 67%, and 73%, respectively. Malformations with low Virginia RAS scores of 0-1 had significantly higher obliteration rates than those with intermediate or high scores of 2-4 (p = 0.001). 
Predictors of AVM Obliteration
Univariate Cox proportional-hazards regression analysis identified no embolization preradiosurgery, decreased AVM volume, increased prescription dose, single draining vein, lower RBAS score, and lower Virginia RAS score as statistically significant predictors of obliteration. Multivariate analysis revealed factors independently associated with obliteration to be as follows: no preradiosurgery embolization (p < 0.001), decreased AVM volume (p = 0.005), single draining vein (p = 0.013), lower RBAS score (p = 0.016), and lower Virginia RAS score (p = 0.001). Table 3 details the results of the univariate and multivariate Cox proportional-hazards regression analyses for predictors of obliteration.
Repeat Radiosurgery
Repeat radiosurgery was performed in 50 patients (10.0%) with incompletely obliterated AVMs, including 48 patients (9.6%) with one repeat treatment and 2 patients (0.4%) with two repeat treatments. The first repeat radiosurgical parameters were a median AVM volume of 0.9 cm 3 (range 0.1-6.9 cm 3 ), median prescription dose of 20 Gy (range 5-27 Gy), median maximum dose of 36 
Postradiosurgery Hemorrhage
Over 2158 risk years, 28 patients had 30 hemorrhages following radiosurgery, consisting of one hemorrhage in each of 26 patients and two hemorrhages in each of 2 patients, for an annual postradiosurgery hemorrhage rate of 1.4%. Seven patients experienced clinical deterioration due to postradiosurgery hemorrhage (1.4%). There were no cases of hemorrhage after complete AVM obliteration. Logistic regression analysis demonstrated increased AVM volume, decreased prescription dose, multiple draining veins, higher RBAS score, and higher Virginia RAS score as statistically significant predictors of postradiosurgery hemorrhage. Increased AVM volume (p = 0.034) and lower prescription dose (p = 0.006) were determined to be independently associated with postradiosurgery hemorrhage based on multivariate analysis. Table 4 details the results of the univariate and multivariate logistic regression analyses for predictors of postradiosurgery hemorrhage.
Radiation-Induced Changes and Cyst Formation Following Radiosurgery
Radiation-induced change was identified on postradiosurgery MRI in 184 patients (36.7%) at a mean of 12.2 months, median of 10.9 months, and range of 0.2-61.5 months following radiosurgery. The amount of time that the RICs endured was a mean of 22.1 months, median of 16.5 months, and range of 2.4-128.3 months. Radiationinduced changes were symptomatic in 41 patients (8.2%) consisting of headache in 14 patients (2.8%), neurological deficit in 18 (3.6%), and seizures in 9 (1.8%). Symptomatic RICs were transient in 34 patients (6.8%) and permanent in 7 (1.4%). Permanent RICs consisted of focal neurological deficits in 4 patients (0.8%) and seizures in 3 (0.6%). Excluding all patients with less than 2 years of radiological follow-up, even those with AVM obliteration, the rates of cumulative, symptomatic, and permanent RICs were 38.6% (160 of 414 patients), 8.2% (34 of 414 patients), and 1.4% (6 of 414 patients), respectively. Logistic regression analysis demonstrated no preradiosurgery hemorrhage, increased AVM volume, decreased prescription dose, higher RBAS score, and higher Virginia RAS score as statistically significant predictors of postradiosurgery RIC. Multivariate analysis demonstrated no preradiosurgery hemorrhage (p = 0.011), decreased prescription dose (p = 0.038), and higher Virginia RAS score (p = 0.001) to be independent predictors of RIC following radiosurgery. Table 5 details the results of the univariate and multivariate logistic regression analyses for predictors of RIC following radiosurgery. Cyst formation postradiosurgery was evident in 6 patients (1.2%) but was only symptomatic, resulting in new-onset seizures, in 1 patient (0.2%). No surgical intervention was undertaken for any of the patients with postradiosurgery cysts. 
Clinical Outcomes Following Radiosurgery
Overall clinical follow-up was a mean of 77.4 months (6.5 years), median of 61.6 months (5.1 years), and range of 6.8-239.4 months (0.6-20.0 years). Patients presenting with seizures had decreased seizure frequency (56 patients) or were seizure-free (26 patients) following radiosurgery in 16.3% of cases. Increased seizure frequency occurred in 6 patients (1.2%), and new-onset seizures were observed in 9 patients (1.8%) after radiosurgery (38 patients were stable from a seizure standpoint). Clinical improvement following radiosurgery was reported in 108 patients (21.5%). Permanent clinical deterioration was observed in 28 patients (5.6%); combined with 30 patients with transient clinical decline (6.0%), the overall rate of temporary and permanent clinical morbidity following radiosurgery was 11.6%.
Selected Low-Grade AVM Subgroups
As listed above and shown in Fig. 2 , low-grade AVMs without embolization before radiosurgery had significantly higher obliteration rates than those treated with prior embolization (45% vs 24% at 3 years, 74% vs 34% at 5 years, p < 0.001). The rates of RIC were not significantly different between the nonembolized and embolized cohorts including cumulative (36.4% vs 37.6%, p = 0.912), symptomatic (9.2% vs 4.0%, p = 0.103), and permanent (1.5% vs 1.0%, p = 1.000) RICs. The postradiosurgery hemorrhage risks for nonembolized and embolized lesions were 1.4% and 1.5%, respectively.
The respective 3-and 5-year obliteration rates were 39% and 65% for low-grade AVMs with superficial venous drainage and 50% and 69% for those with deep venous drainage (p = 0.130). The rates of RIC were not significantly different between the lesions with superficial and those with deep venous drainage including cumulative (37.6% vs 33.3%, p = 0.477), symptomatic (7.2% vs 8.4%, p = 0.824), and permanent RICs (0.9% vs 1.5%, p = 1.000). The postradiosurgery hemorrhage risks for the superficial and deep venous drainage cohorts were 1.5% and 1.1%, respectively.
The respective 3-and 5-year obliteration rates were 43% and 65% for low-grade AVMs with a noneloquent location and 38% and 67% for those with an eloquent location (p = 0.802). The rates of RIC were not significantly different between the lesions located in noneloquent and those located in eloquent cortex including cumulative (33.9% vs 40.7%, p = 0.145), symptomatic (6.7% vs 10.3%, p = 0.203), and permanent RIC (1.3% vs 1.5%, p = 1.000). The postradiosurgery hemorrhage risks for the noneloquent and eloquent cohorts were 1.4% and 1.3%, respectively.
Discussion
Low-grade AVMs, SM Grade I or II, are often potentially treatable via all three standard therapeutic modalities, including endovascular embolization, microsurgical extirpation, and radiosurgery. The natural history of low-grade compared with high-grade AVMs remains the subject of controversy. The traditional dogma that smaller AVMs are more likely to rupture because of higher intranidal pressure has been challenged by natural history studies demonstrating higher rates of rupture in larger lesions. 39 Smaller AVMs may be more likely to present with hemorrhage, but recent studies have shown that large AVMs can be associated with higher prospective hemorrhage rates. 18, 44 Nevertheless, the combination of the young patient age at which most AVMs are diagnosed and the natural history of AVMs exposes patients harboring these lesions to a substantial lifetime risk of hemorrhagerelated morbidity and mortality.
Microsurgical Removal of Low-Grade AVMs
In general, microsurgical removal represents an excellent treatment approach for low-grade AVMs. Early microsurgical series reported extremely low surgical complication rates, although in relatively few patients. 12 Sisti et al. resected 67 small AVMs, less than 3 cm in diameter, with a morbidity of 1.5% and no mortality. 38 Heros et al. reported 0% early and late neurological morbidity following microsurgical removal of Grade I AVMs (12 patients) and 5.7% early and 2.9% late neurological morbidity after the resection of Grade II AVMs (35 patients). 13 Morgan et al. described their surgical outcomes in 220 patients with low-grade AVMs, 8% of whom underwent preoperative embolization. 23 Overall morbidity and mortality combined was 1.4%: 0.6% (1 of 180 patients) for noneloquent and 5% (2 of 40 patients) for eloquent AVMs. As the authors note, two eloquent AVMs were managed conservatively owing to a perceived high risk of neurological injury. Therefore, the adjusted rate of operative morbidity for eloquent AVMs may have been as high as 9.5%.
The impressive results of many microsurgical AVM series have resulted in an aggressive stance by some cerebrovascular surgeons heavily favoring open resection over radiosurgery for low-grade AVMs. 7 Pikus et al. treated 72 AVM cases with microsurgery, including 13 patients with SM Grade I, 13 with Grade II, and 28 with Grade III lesions. 29 For AVMs smaller than 3 cm in diameter, there was no operative morbidity, and among all Grade I-III AVMs in the series, there was 1 case of operative morbidity (1.9%). After comparing their results with those in the available radiosurgical AVM literature at the time, the authors concluded that microsurgery was superior to radiosurgery for the treatment of low-and intermediate-grade AVMs. In contrast to the very low complication rates reported in the aforementioned studies, neurological decline or mortality rates of 8.9% (5 of 56 patients) for SM Grade I AVMs and 24.4% (30 of 123 patients) for Grade II AVMs were reported by Lawton et al. 19 Beyond surgical technique differences, variations in morbidity and mortality rates in microsurgical series for SM Grade I and II AVMs may be attributable to patient selection, patient attributes (for example, age and medical comorbidities), study size, duration of follow-up, and rigorousness of follow-up.
Endovascular Embolization of Low-Grade AVMs
Low-grade AVMs, by nature of their relatively smaller size and frequent superficial venous drainage, can be successfully treated with stand-alone embolization therapy in select cases. In highly selected case series, oblitera- tion rates with permanent embolic agents such as ethylene vinyl copolymer, otherwise known as Onyx (ev3), are up to 50%. 35 More accurate estimates of complete AVM occlusion with embolization alone are significantly lower, around 20%-30%, even for low-grade lesions. 16, 28 While curative embolization of low-grade AVMs is feasible, the associated morbidity rate, over 10% in some series, and the risk of recanalization after initially complete angiographic occlusion remain barriers to its widespread acceptance as a primary management approach. 16, 25, 28, 35 As our understanding of the risks and benefits of endovascular embolization has advanced over time, we have typically adopted a conservative endovascular approach in the management of low-grade AVMs. Additionally, data from our radiosurgery experience, corroborated by similar reports from other centers, have demonstrated a deleterious effect of embolization on subsequent radiosurgical obliteration rates. 2, 8, 37 At our institution, preradiosurgery embolization is reserved for lesions supplied by high-flow feeding arteries harboring perinidal or intranidal aneurysms and those with intranidal arteriovenous shunts. For the majority of low-grade AVMs, the neoadjuvant role of embolization prior to microsurgery or radiosurgery seems similarly minor. However, as advances in endovascular technology continue to be made and our understanding of multimodality AVM treatment continues to evolve, the impact of embolization on AVMs, such as after rather than before radiosurgery, has yet to reach its maximum potential. 
Role of Radiosurgery for Treatment of SM Grade I and II AVMs
In a large cohort of low-grade AVM patients with long-term radiological follow-up (median 47.9 months), we reported a cumulative obliteration rate of 76%, which was 66% at 5 years and 80% at 10 years based on KaplanMeier survival analysis. No preradiosurgery obliteration (p < 0.001), decreased AVM volume (p = 0.005), single draining vein (p = 0.013), lower RBAS score (p = 0.016), and lower Virginia RAS score (p = 0.001) were identified as independent predictors of obliteration. As stated earlier, embolization prior to radiosurgery is a well-known deterrent to successful AVM obliteration. 2, 8, 37 While beam scattering or absorption by embolic agents has been hypothesized as a possible explanation for this phenomenon, in vitro studies performed by Bing et al. did not demonstrate significant reductions in radiation dose to embolized AVMs. 3 Alternate mechanisms for decreased radiosurgical obliteration of embolized AVMs include postembolization AVM recanalization or desensitization to radiation, embolization-induced angiogenesis, and increased difficulty of radiosurgical targeting due to an embolic agent artifact or alterations in the angioarchitecture. 1, 17, 46, 48 Smaller AVM volume is a widely accepted predictor of obliteration and is reconfirmed by the present study.
10,14,32 Singular venous drainage probably indicates a more compact nidus, which enhances the efficacy of radiosurgical targeting.
The biggest disadvantage of radiosurgery compared with microsurgery is the latency period between radiosurgery and obliteration (typically 6 months-3 years) during which patients remain at risk for AVM rupture. In the majority of radiosurgery AVM series, the hemorrhage risk during the latency period appears to compare favorably with the natural history. 15, 20, 21, 50 The annual postradiosurgery hemorrhage risk of 1.4% in our series is lower than the 2%-4% per year rupture rate reported in AVM natural history studies. 4, 11, 27, 31 Increased AVM volume (p = 0.034) and lower prescription dose (p = 0.006) were independent predictors of postradiosurgery hemorrhage. The low annual postradiosurgery hemorrhage rate in the current study suggests that irradiation of SM Grade I and II AVMs results in vascular stabilization, thereby resulting in partial protection from latency period hemorrhage. However, some of the protection may be a result of complete obliteration occurring in AVMs for which there is a delay in recognizing obliteration in between fixed intervals of radiological assessment.
Postradiosurgery RIC was symptomatic in 8.2% and permanent in 1.4% of patients, with multivariate analysis determining that no preradiosurgery hemorrhage (p = 0.011), a decreased prescription dose (p = 0.038), and a higher Virginia RAS score (p = 0.001) were independently associated with RIC. While not definitively proven, AVM rupture prior to radiosurgery may create a perilesional gliotic margin, which protects adjacent normal parenchyma from RIC. 47 The overall rate of permanent clinical decline was 5.6%, which included 3% of patients with new-onset or exacerbation of preexisting seizures.
In a similar study of 217 low-grade AVM patients treated with radiosurgery, Kano et al. reported actuarial obliteration rates of 58%, 87%, and 93% at 3, 5, and 10 years, respectively.
14 Despite a similar median AVM volume and prescription dose, Kano et al. were able to achieve a higher obliteration rate than we did in the current study. Note that the aforementioned study excluded all patients with preradiosurgery embolization, which we determined was an independent predictor of decreased obliteration (p < 0.001) and was used in 20% of the AVMs in our series. The overall obliteration rate of nonembolized AVMs in our series was 81% (324 of 401 patients). The postradiosurgery hemorrhage rate reported by Kano et al. was 2.3% per year but was reduced significantly from 3.9% in the 1st year to 0.6% in the 2nd year after treatment.
14 While no patients developed permanent neurological deficits from RIC, 6 patients died of latency period hemorrhage for a mortality rate of 2.8%.
Using retrospective studies, we had difficulty accurately comparing the complication rates between microsurgery and radiosurgery series. 12, 13, 23, 29 For instance, because of selection biases of the treating physicians and institutional referral patterns, the AVM characteristics of radiosurgery and microsurgery cohorts can differ significantly. In the microsurgical series by Morgan et al., 18% (40 of 220) of the AVMs were in eloquent cortex. 23 By contrast, 41% of the patients in our series had AVMs in an eloquent location, which is known to negatively impact microsurgical outcomes but was not found to increase radiosurgery-induced complications in our cohort (p = 0.201). 26, 36 Nataf et al. compared the microsurgery and radiosurgery outcomes in two AVM cohorts, each composed of 39 patients, which were matched for age, initial symptoms, AVM size, AVM location, SM grade, and prior embolization. 24 The obliteration rate was higher in the microsurgery cohort (91%) than in the radiosurgery cohort (81%), although the difference was not statistically significant (p = 0.10). Neurological deficit was more common in the microsurgery group (p < 0.001), whereas posttreatment AVM rupture was higher in the radiosurgery group (p = 0.04). Additionally, the functional outcomes at 12 and 24 months, as measured by the Glasgow Outcome and modified Rankin Scales, were better in the radiosurgery cohort.
Nevertheless, for low-grade AVMs, especially SM Grade I lesions, evaluation for microsurgical removal at an experienced cerebrovascular center should remain the initial step in patient management. Those patients deemed unsuitable for surgical treatment, because of AVM location or angioarchitecture or medical comorbidities, and those refusing craniotomy can be subsequently treated with radiosurgery. 34 Moreover, patients with SM Grade I or II AVM with residual nidus after resection should be considered for radiosurgery. Finally, pending the publication of results of the ARUBA trial (A Randomized Trial of Unruptured Brain Arteriovenous Malformations), it remains to be determined whether conservative management is superior to any intervention for unruptured AVMs, which comprise 50% of our low-grade AVM cohort. 22 
Study Limitations
Our study is inherently limited by the biases associated with a retrospective single-center review of a single cohort without a comparable control cohort. The lack of prospective randomization results in a selection bias, which makes it difficult to obtain a precise comparison between our radiosurgical outcomes and those associated with AVM natural history and with other AVM treatments. Without randomization, we were unable to accurately ascertain the effect of prior embolization on radiosurgical efficacy. Additionally, 16% of patients with documented complete AVM obliteration did not have angiographic confirmation. While DSA remains the gold standard for evaluating the patency of an AVM nidus, Pollock et al. showed that for AVM neuroimaging follow-up, MRI has a 100% specificity and 91% negative predictive value, as compared with DSA. 33 Moreover, the precedent of documenting AVM obliteration using MRI alone has been set by similar studies from other institutions. 14 We acknowledge that despite the long-term clinical follow-up of patients in our study, the clinical data were not as complete as the radiological follow-up. Therefore, we were unfortunately unable to precisely determine the effect of either postradiosurgery hemorrhage or symptomatic RIC on a patient's functional status.
By including those patients with less than 2 years of radiological follow-up who had AVM obliteration and excluding others with short follow-up, we may have favorably biased our results toward higher obliteration rates. However, excluding patients with less than 2 years of followup would have biased results the other way, that is, toward lower rates of obliteration. In an attempt to maintain equipoise when reporting our results, we included the obliteration and RIC rates of all patients, save those with less than 2 years of follow-up, even those with obliteration. In our cohort of low-grade AVMs, the rates of symptomatic (8.2%) and permanent (1.4%) RICs were the same with both exclusion criteria. We also note that the exclusion of patients with less than 2 years' follow-up may have biased our results toward more favorable outcomes by potentially overestimating obliteration rates and underestimating RIC rates. Lastly, we emphasize that this study was not designed to compare radiosurgical with microsurgical outcomes for low-grade AVMs. While such comparisons will nonetheless be made, an accurate comparison of the two approaches will ultimately rely on future prospective studies.
Conclusions
Spetzler-Martin Grade I and II AVMs represent the substratification of AVMs most amenable to successful treatment, with the lowest risk of morbidity associated with microsurgery or radiosurgery. Because of the significant lifetime hemorrhage risk posed even by low-grade AVMs and their relatively favorable risk-to-benefit profile, as compared with Grade III-V lesions, aggressive intervention is typically pursued especially in cases of prior rupture. While microsurgery should be considered for low-grade AVMs given the procedure's generally low complication rate and immediate impact, we have found radiosurgery to be a safe and effective alternative. Embolization should be used selectively because of its detrimental effect on radiosurgical outcomes. For low-grade AVMs, embolization to reduce nidus size is generally not warranted prior to stereotactic radiosurgery. Although successful treatment with radiosurgery manifests in a delayed fashion, irradiation of AVMs can provide a degree of vascular stabilization during the latency period and eliminates the hemorrhage risk once obliteration is achieved.
